(19)
(11) EP 2 344 892 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.11.2014 Bulletin 2014/46

(45) Mention of the grant of the patent:
21.05.2014 Bulletin 2014/21

(21) Application number: 09740779.5

(22) Date of filing: 30.09.2009
(51) International Patent Classification (IPC): 
G01N 33/94(2006.01)
(86) International application number:
PCT/US2009/058913
(87) International publication number:
WO 2010/039754 (08.04.2010 Gazette 2010/14)

(54)

Glucuronidated acetaminophen as a marker of hepatic disorders

Glucuronidiertes Acetaminophen als Marker für Lebererkrankungen

Acétaminophène glucuronidé en tant que marqueur de troubles hépatiques


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 01.10.2008 US 194835 P

(43) Date of publication of application:
20.07.2011 Bulletin 2011/29

(73) Proprietor: The Arizona Board Of Regents On Behalf Of The University Of Arizona
Tucson, AZ 85721-0158 (US)

(72) Inventor:
  • CHERRINGTON, Nathan
    Oro Valley,AZ 85755 (US)

(74) Representative: Lee, Nicholas John et al
Kilburn & Strode LLP 20 Red Lion Street
London WC1R 4PJ
London WC1R 4PJ (GB)


(56) References cited: : 
   
  • EL-AZAB G ET AL: "Acetaminophen plasma level after oral administration in liver cirrhotic patients suffering from schistosomal infection" INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 34, no. 7, 1996, pages 299-303, XP8117148 ISSN: 0946-1965
  • FORREST J A H ET AL: "PARACETAMOL METABOLISM IN CHRONIC LIVER DISEASE" EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, SPRINGER VERLAG, DE, vol. 15, no. 6, 1 November 1979 (1979-11-01), pages 427-431, XP008117151 ISSN: 0031-6970 [retrieved on 2004-12-12]
  • GMYREK D: "Results of administration of large oral dose of paracetamol to children with infectious hepatitis" DTSCHXSESUNDH.WE 1971, vol. 26, no. 11, 1971, pages 503-508, XP008117173
  • CORCORAN G B ET AL: "OBESITY AS A RISK FACTOR IN DRUG-INDUCED ORGAN INJURY INCREASED LIVER AND KIDNEY DAMAGE BY ACETAMINOPHEN IN THE OBESE OVERFED RAT" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 241, no. 3, 1987, pages 921-927, XP8117295 ISSN: 0022-3565
  • LICKTEIG ANDREW J ET AL: "Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease" DRUG METABOLISM AND DISPOSITION, vol. 35, no. 10, October 2007 (2007-10), pages 1970-1978, XP002563826 ISSN: 0090-9556 cited in the application
  • SHINODA SHIGEO ET AL: "Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain" BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 30, no. 1, January 2007 (2007-01), pages 157-161, XP002563827 ISSN: 0918-6158
  • LIANG M Z ET AL: "Pharmacokinetics of Mycophenolic Acid and Its Glucuronide After a Single and Multiple Oral Dose of Mycophenolate Mofetil in Chinese Renal Transplantation Recipients" TRANSPLANTATION PROCEEDINGS, ORLANDO, FL, US, vol. 38, no. 7, 1 September 2006 (2006-09-01), pages 2044-2047, XP025008414 ISSN: 0041-1345 [retrieved on 2006-09-01]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).